Ho S Lee

Address:

3439 Plum Tree Dr APT G, Ellicott City, MD 21042

Phone:

(410)7991477

VIN:

4T1BE46K57U665503

Make:

TOYOTA

Model:

CAMRY

Year:

2007

US Patent:

D3645568, Nov 28, 1995

Filed:

Aug 30, 1994

Appl. No.:

D/027836

Inventors:

Ho Lee - Bowie MD
David M. Hurr - Falls Church VA

Assignee:

Snoloc Corporation - Upper Marlboro MD

US Classification:

D 8499

US Patent:

56339828, May 27, 1997

Filed:

Oct 21, 1996

Appl. No.:

8/734210

Inventors:

Kalyan Ganesan - Germantown MD
Ho Lee - San Diego CA
Prabhat Gupta - Germantown MD

Assignee:

Hughes Electronics - Los Angeles CA

International Classification:

G10L 900
G10L 506

US Classification:

395 242

Abstract:

The perception of speech processed by a CELP based coder, such as a VSELP coder, when operating in noisy background conditions is improved by removing swirl artifacts during silence periods. This is done by removing the low frequency components of the input signal when no speech is detected. A speech activity detector distinguishes between a periodic signal, like speech, and a non-periodic signal, like noise by using most of the VSELP coder internal parameters to determine the speech or non-speech conditions. To prevent the VSELP coder from determining pitches for non-periodic signals, a high pass filter is applied to the input signal to remove the pitch information for which the VSELP coder searches.

US Patent:

20200230218, Jul 23, 2020

Filed:

Aug 30, 2019

Appl. No.:

16/556957

Inventors:

- Seoul, KR
Jeong Kuen Song - Gaithersburg MD, US
Seung-Wook Shin - Clarksburg MD, US
Kwan Hee Lee - Las Vegas NV, US
Ho June Lee - Potomac MD, US

Assignee:

L & J Bio Co., Ltd. - Seoul

International Classification:

A61K 38/57
A61K 38/17
A61P 25/28
A61K 38/38
A61K 38/46
A61K 38/50

Abstract:

The present application discloses a method for treating a protein deficiency in the central nervous system of a subject in need thereof, comprising systemically administering to the subject a therapeutically effective dose of a fusion polypeptide comprising the first protein, wherein the fusion polypeptide comprises: (a) the first protein; (b) a second protein that provides extended circulation-lifetime in vivo and (c) blood brain barrier crossing facilitating peptide; wherein the fusion polypeptide crosses the blood brain barrier (BBB).